Publication:

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure

Date

Date

Date
2017
Journal Article
Published version

Citations

Citation copied

Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., Rodriguez, J., Brunton, H., Kmarashev, J., Levesque, M. P., Dummer, R., Frederick, D. T., Andrews, M. C., Cooper, Z. A., Flaherty, K. T., … Wellbrock, C. (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9, 1011–1029. https://doi.org/10.15252/emmm.201607156

Abstract

Abstract

Abstract

Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a "MITF-high" phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulations of the de novo resistance "AXL-high" phenotype. > 50% of melanomas progress with enriched "AXL-high" populations, and because AXL is linked to de-differentiation and invasiveness avoiding an "AXL-high relapse" is desirable. We discovered that phenotype heterogeneity is supported during

Additional indexing

Creators (Authors)

  • Smith, Michael P
    affiliation.icon.alt
  • Rowling, Emily J
    affiliation.icon.alt
  • Miskolczi, Zsofia
    affiliation.icon.alt
  • Ferguson, Jennifer
    affiliation.icon.alt
  • Spoerri, Loredana
    affiliation.icon.alt
  • Haass, Nikolas K
    affiliation.icon.alt
  • Sloss, Olivia
    affiliation.icon.alt
  • McEntegart, Sophie
    affiliation.icon.alt
  • Arozarena, Imanol
    affiliation.icon.alt
  • von Kriegsheim, Alex
    affiliation.icon.alt
  • Rodriguez, Javier
    affiliation.icon.alt
  • Brunton, Holly
    affiliation.icon.alt
  • Kmarashev, Jivko
    affiliation.icon.alt
  • Levesque, Mitchell P
    affiliation.icon.alt
  • Dummer, Reinhard
    affiliation.icon.alt
  • Frederick, Dennie T
    affiliation.icon.alt
  • Andrews, Miles C
    affiliation.icon.alt
  • Cooper, Zachary A
    affiliation.icon.alt
  • Flaherty, Keith T
    affiliation.icon.alt
  • Wargo, Jennifer A
    affiliation.icon.alt
  • Wellbrock, Claudia
    affiliation.icon.alt

Journal/Series Title

Journal/Series Title

Journal/Series Title

Volume

Volume

Volume
9

Number

Number

Number
8

Page range/Item number

Page range/Item number

Page range/Item number
1011

Page end

Page end

Page end
1029

Item Type

Item Type

Item Type
Journal Article

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Language

Language

Language
English

Publication date

Publication date

Publication date
2017-08

Date available

Date available

Date available
2017-08-30

Publisher

Publisher

Publisher

ISSN or e-ISSN

ISSN or e-ISSN

ISSN or e-ISSN
1757-4676

OA Status

OA Status

OA Status
Gold

Free Access at

Free Access at

Free Access at
DOI

PubMed ID

PubMed ID

PubMed ID

Citations

Citation copied

Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., Rodriguez, J., Brunton, H., Kmarashev, J., Levesque, M. P., Dummer, R., Frederick, D. T., Andrews, M. C., Cooper, Z. A., Flaherty, K. T., … Wellbrock, C. (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9, 1011–1029. https://doi.org/10.15252/emmm.201607156

Gold Open Access
Loading...
Thumbnail Image

Files

Files

Files
Files available to download:1

Files

Files

Files
Files available to download:1
Loading...
Thumbnail Image